Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren + amlodipine versus amlodipine in essential hypertension inadequately controlled on amlodipine
2006-006068-44Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aliskiren and amlodipine in essential hypertension (3 arms), sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started Aug 2008; status: completed.
02
Drugs
aliskirenamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2006-006068-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006068-44.